REAGILA’s Effects on Primary and Secondary Negative Symptoms: Pseudospecificity

REAGILA’s Effects on Primary and Secondary Negative Symptoms: Pseudospecificity

Cariprazine is effective on a broad range of schizophrenia symptoms including negative symptoms^1,5-7

As shown in the cariprazine negative symptom study, negative symptom control with cariprazine is not attributed to an improvement in positive symptom control¹

Negative symptom control is also not attributed to an improvement in depressive symptom control¹

Negative symptom control is also not attributed to an improvement in EPS¹

In this section

What is the Pseudospecificity Problem?

So, What’s the Difference?

How Can Genuine Negative Symptom Treatment Effects Be Demonstrated?

Real Negative Symptom Improvement

REAGILA’s Effects on Primary and Secondary Negative Symptoms: Pseudospecificityadmin2021-06-04T11:13:33+00:00

This information is only accessible for healthcare professionals seeking more information on Reagila®(cariprazine) for the treatment of schizophrenia in adult patients. Please register here for further clinical and practical information.

Werkingsmechanisme

Klinische data

REAGILA’s Effects on Primary and Secondary Negative Symptoms: Pseudospecificity

In this section